Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 22, 2020

View Archived Issues

MARCH1 regulates IFN-I response and adaptive immunity in malaria parasite infections in mice

Notch4 key to asthma's T-cell derailment

A tense defense

New phase I trial evaluates Apomab theranostic for lung and ovarian cancer

Bristol-Myers Squibb presents new MGAT2 inhibitors

TRACON presents data for envafolimab in MSI-H/dMMR colorectal cancer

REVOLUTION Medicines patents SOS1 inhibitors

Eli Lilly initiates phase II study of LY-3041658 in hidradenitis suppurativa

Ensysce Biosciences discloses new compounds for ADHD

Silverback Therapeutics identifies TGFBR inhibitors

New compounds for cancer presented by Virginia Commonwealth University

Phase Ib data for DNL-201 in patients with PD with and without LRRK2 mutations

Metastatic migration is collective effort for colorectal cancers

Discovery of novel selective HDAC6-selective inhibitor, PTG-0861

AV-101 reverses L-Dopa-induced dyskinesia in parkinsonian monkeys

New phase II study evaluates encaleret for autosomal dominant hypocalcemia type 1

HanX begins phase I trial in China with ON-123300

FDA clears IND for study of inhaled Ampion in COVID-19 patients with respiratory distress

Biallelic loss of CFAP58 causes flagellar axoneme and asthenoteratozoospermia

ARCA submits IND for phase IIb/III evaluation of AB-201 for COVID-19

Blueprint reports data from EXPLORER and PATHFINDER trials of Ayvakit in systemic mastocytosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for July 31, 2026.
AIDS 2026: New targets for metabolic dysfunction despite ART
BioWorld
Although antiretroviral therapy (ART) can suppress HIV to undetectable levels, a growing body of evidence suggests that the virus leaves a lasting biological...
Tuojie Biotech (Shanghai) synthesizes new SARM1 inhibitors
BioWorld Science
Tuojie Biotech (Shanghai) Co. Ltd. has prepared and tested NAD(+) hydrolase SARM1 (SAMD2; MyD88-5) inhibitors found to be potentially useful for the treatment of...
Jingxin discloses new muscarinic and sigma receptor agonists
BioWorld Science
Shanghai Jingxin Biopharmaceutical Co. Ltd. and Zhejiang Jingxin Pharmaceutical Co. Ltd. have synthesized new muscarinic acetylcholine receptor and sigma receptor...
Death in Chinese gene-editing trial exposes ethical fault lines
BioWorld
The death of a 6-year-old girl after receiving an experimental brain-directed gene-editing therapy at the Xinhua Hospital in Shanghai has reopened debate over how...